Dear Dr. Roach: My husband recently passed away one week after his 80th birthday. According to his death certificate, he died of lung cancer (not a surprise) and chronic myelomonocytic leukemia (CMML) ...

– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...

Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With ...

Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 ...

Mike and Sofia Segal, who immigrated to the U.S. from present-day Ukraine in 1978, lead foundation that supports overlooked and underfunded causes, including rare diseases RYE BROOK, N.Y., Oct. 25, ...

Safety findings from the study were comparable with those previously observed with IV decitabine. The most common treatment-emergent adverse events of thrombocytopenia, neutropenia and anemia were ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dr. Roach: My husband recently passed away one week after his 80th birthday. According to his death certificate, he died of lung ...